News

Phaware, a global advocacy organization, is launching a special podcast series to raise awareness of pulmonary arterial hypertension (PAH) caused by the use of methamphetamine, a stimulant drug known for its psychoactive effects. Methamphetamine-induced PAH is now known simply as Meth-PAH. The six-episode series, part of the “…

Pulmonary endarterectomy (PEA), a surgery to remove blood clots in individuals with chronic thromboembolic pulmonary hypertension (CTEPH), may be more effective in improving pulmonary circulation and heart function than balloon pulmonary angioplasty (BPA), according to a recent study. After treatment, a higher proportion of patients in the BPA group…

Stanford University has been awarded a grant from the U.S. National Institutes of Health (NIH) to begin a Phase 2 clinical trial of pulmonary arterial hypertension (PAH) treatment tiprelestat, the treatment’s developer announced. Tiakis Biotech said tiprelestat was found to be safe in earlier clinical trials involving more…

Corvista Health’s point-of-care device can detect cases of pulmonary hypertension (PH) that other noninvasive diagnostic tools miss, according to a recent case series. “By enabling physicians to identify pulmonary hypertension within minutes, non-invasively, and even when traditional tests fail, we are offering a new standard of care that…

Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to mosliciguat, an investigational inhalation therapy that Pulmovant is developing to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The MHLW gives this designation to experimental medicines intended to treat conditions affecting fewer than…

People with pulmonary hypertension (PH) face significant obstacles when seeking timely care, with barriers arising at each stage from symptom onset through diagnosis and treatment, according to interviews with patients and healthcare providers. Those barriers included a lack of PH knowledge among non-specialists, symptoms being dismissed, and limited access…

United Therapeutics and Mannkind Corporation are teaming up to develop a new inhaled therapy for pulmonary hypertension. The two companies worked together to develop Tyvaso DPI, a dry powder formulation that was approved in the U.S. in 2022 to improve exercise ability in people with…

Cereno Scientific has received fast track designation from the U.S. Food and Drug Administration (FDA) for CS1, its therapy candidate for pulmonary arterial hypertension (PAH). “We are very pleased to have achieved Fast Track designation for CS1, which both validates the strength of our CS1 program and supports…

At diagnosis, Black people with pulmonary arterial hypertension (PAH) tend to have more severe disease than their non-Black counterparts, a new U.S. study shows. The study, done using data from the University of Illinois Health Pulmonary Hypertension Clinic, further indicated that Black people being evaluated for PAH also tend…

A 68-year-old man with severe pulmonary arterial hypertension, or PAH — high blood pressure in the lungs — and multiple coexisting conditions saw considerable improvements after being given combination therapy with four different medications, a case study from the U.S. reports. Gains were seen in blood flow measures, the…

Treatment with a combination of sildenafil and statins improved exercise capacity and reduced pulmonary arterial pressure in people with pulmonary hypertension (PH) secondary to chronic obstructive pulmonary disease (COPD) — a condition known for short as COPD-PH — according to a review study by scientists in China. These findings,…

Yutrepia (inhaled treprostinil), an inhaled dry powder formulation of treprostinil for pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH) associated with interstitial lung disease (PH-ILD), has been prescribed to more than 900 people with PAH and PH-ILD since its approval in the U.S. in May, according to…